<link rel="stylesheet" href="styles.f3b1fba60ec7970c.css">

Radiation Therapy Outcomes of the National Protocol in Childhood Neuroblastomas: Turkish Society for Radiation Oncology Hematological Oncology, Pediatric Oncology, and TBI Working Group Study (TROD 03-004)

dc.contributor.authorGultekin, Melis
dc.contributor.authorYilmaz, Melek Tugce
dc.contributor.authorYildiz, Ferah
dc.contributor.authorKamer, Serra
dc.contributor.authorDemiral, Ayse Nur
dc.contributor.authorGursel, Bilge
dc.contributor.authorGural, Zeynep
dc.contributor.authorAgaoglu, Fulya
dc.contributor.authorBirgi, Sumerya Duru
dc.contributor.authorCaloglu, Vuslat Yurut
dc.contributor.authorOlgun, Nur
dc.contributor.authorAksoylar, Serap
dc.contributor.authorAnacak, Yavuz
dc.date.accessioned2026-11-05T11:06:39Z
dc.date.issued2026
dc.description.abstractPurpose: The Turkish Pediatric Oncology Group (TPOG) established a risk-adapted national neuroblastoma (NBL) treatment strategy in 2003 and updated it in 2009 and 2020 to optimize outcomes in NBL. With this study, we aimed to evaluate the oncological outcomes Methods and Materials: We retrospectively evaluated 135 NBL patients who received adjuvant radiation therapy between May 2004 and May 2018 from 7 tertiary pediatric oncology centers in Tu & euro;rkiye. Patients were treated according to TPOG-NBL2003 and TPOGNBL2009 protocols. All statistical analyses were performed using SPSS 23.0 software (SPSS). Results: The median age was 42 months, and 58 (43%) patients were female. The adrenal medulla was the primary tumor location in 103 (76%) patients. Only 14 patients had intermediate-risk disease, whereas 121 had high-risk disease. The median follow-up was 67.3 months. The 2- and 5-year overall survival (OS) rates were 84% and 68%, locoregional recurrence-free survival (LRRFS) rates were 81% and 66%, distant metastasis-free survival rates were 76% and 56%, and event-free survival (EFS) rates were 74% and 54%, respectively.
dc.description.issue2
dc.description.pages176-187
dc.description.volume16
dc.identifier.doi10.1016/j.prro.2025.10.003
dc.identifier.issn1879-8500
dc.identifier.urihttps://doi.org/10.1016/j.prro.2025.10.003
dc.identifier.urihttps://openaccess.acibadem.edu.tr/handle/11443/11372
dc.identifier.wosWOS:001717648400001
dc.language.isoen
dc.publisherELSEVIER SCIENCE INC
dc.relation.conferenceAnnual Meeting of the Pediatric-Radiation-Oncology-Society (PROS)
dc.relation.hasversion10.1016/j.prro.2025.10.003
dc.relation.ispartofPRACTICAL RADIATION ONCOLOGY
dc.subjectHIGH-RISK NEUROBLASTOMA
dc.subjectLOCAL-CONTROL
dc.subjectSITES
dc.subjectCHEMOTHERAPY
dc.subjectRADIOTHERAPY
dc.subjectRECURRENCE
dc.subjectSURVIVAL
dc.subjectDISEASE
dc.subjectOncology
dc.subjectRadiology, Nuclear Medicine & Medical Imaging
dc.titleRadiation Therapy Outcomes of the National Protocol in Childhood Neuroblastomas: Turkish Society for Radiation Oncology Hematological Oncology, Pediatric Oncology, and TBI Working Group Study (TROD 03-004)
dc.typeArticle
oaire.citation.editionScience Citation Index Expanded (SCI-EXPANDED)
oaire.citation.editionConference Proceedings Citation Index - Science (CPCI-S)
oaire.citation.endPage187
oaire.citation.issue2
oaire.citation.startPage176
oaire.citation.volume16
person.identifier.ridACN-1582-2022
person.identifier.ridAAB-6343-2022
person.identifier.ridB-8518-2011
person.identifier.ridGZH-1201-2022
person.identifier.ridB-8020-2018
person.identifier.ridT-3503-2017
person.identifier.ridJVP-3277-2024
person.identifier.ridQ-1619-2019

Files

Collections